Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals gained 0.990% compared to yesterday.
Pacira Pharmaceuticals is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
As a result the target price of 27 € shows a positive potential of 32.35% compared to the current price of 20.4 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.990% | 7.447% | 10.383% | -1.942% | -6.481% | -45.109% | -66.050% |
| Rockwell Medical Inc. | 0.460% | 2.019% | -10.508% | -51.254% | 12.047% | -37.355% | -93.847% |
| Twist Bioscience Corp | 3.080% | -6.230% | -8.160% | 3.295% | 36.194% | 137.865% | -68.910% |
| Savara Inc. | 1.360% | -2.212% | -5.556% | 85.714% | -16.604% | 116.031% | 211.268% |
Comments
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat